Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05484908 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 29, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 31, 2024 to Dec 31, 2024
    • Study completion date: Aug 31, 2024 to Dec 31, 2024
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 1, 2022 to Aug 12, 2022
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to investigate the efficacy and safety of artificial liver support system treatment for immune checkpoint inhibitors related liver failure in patients with hepatocellular carcinoma.
Trial Details
NCT Number NCT05484908
Lead Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Conditions
(from sponsor)		 Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular, Liver Failure
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov